Ueda2015 hcv dm dr.ahmed ali
Transcript of Ueda2015 hcv dm dr.ahmed ali
![Page 1: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/1.jpg)
![Page 2: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/2.jpg)
HCV – Diabetes mellitus relationship
By
Prof. Ahmed Ali GomaaHead of Tropical Medicine Department
Fayoum University
![Page 3: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/3.jpg)
Introduction of HCV
Role of liver in glucose metabolism
link between HCV and DM.
Effect of control of DM on outcome of HCV
Effect of antiviral therapy on outcome of DM
Conclusion.
![Page 4: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/4.jpg)
Viral hepatitis is the most common cause of liver disease
worldwide.
Hepatitis C virus (HCV) infection is one of the main
causes of chronic liver disease worldwide.
![Page 5: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/5.jpg)
The number of chronically infected personsworldwide is estimated to be about 185 million,but most are unaware of their infection.
The long-term impact of HCV infection ishighly variable, ranging from minimalhistological changes to extensive fibrosis andcirrhosis with or without hepatocellularcarcinoma (HCC).
![Page 6: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/6.jpg)
![Page 7: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/7.jpg)
![Page 8: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/8.jpg)
Global distribution of HCV genotypesSource: WHO Hepatitis C Fact Sheet (July 2012):
![Page 9: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/9.jpg)
Since the discovery of HCV in 1989, interferon α (IFNα)-based therapy has been the only treatment , with overall SVR from 50% to 80% according to HCV genotype, However, the treatment uptake has been generally low due to:
- Numerous side effects
- long duration of therapy
- High cost ,and
- Contraindications to IFN based regimens
![Page 10: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/10.jpg)
Genotype 2 or 3 Genotype 1 or 4
Ribavirin 800 mg + PEG
Interferon* 180mg a2a or
1.5mg. kg, a2b /w, 24 w.
Ribavirin 1000-1200 mg +
PEG Interferon 180mg a2a or
1.5mg. kg, a2b /w 48 w.
(Traditional HCV therapy)
SVR ~ 80% SVR~50%
![Page 11: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/11.jpg)
Protease inhibitorsBoceprevirTelaprevirSimeprivir
NS5Ainhibitor
(Daclatasvir)
RNA polymerase
inhibitor (Sofosbuvir)
![Page 12: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/12.jpg)
Treatment
Options
Recommendation status: Regimen Comments by authors
Option 1 B1: PR + SOF 12 wks „appears the most efficacious and the
easiest to use “
Evaluated in TN Neutrino SVR 96% 27/28
No data in TE
Option 2 B1: PR+ SMV 12 wks + additional PR for either
12 or 36 wks (12 wks SMV + PR; 24 wks total duration for TN & relapsers
including cirrhosis and 48 wks for Prior partials and nulls
including those with cirrhosis)
TN: SVR 89% 31/35
Prior Relapsers: SVR 86% 19/22
Non Responders 57% 41/72
Option 3 B1: PR + DAC 60mg 24 wks
B2: 12 wks TT + additional PR for either 12 or
36 wks: (24 wks total duration for TN & relapsers including
cirrhosis and 48 wks for Prior partials and nulls including those
with cirrhosis)
Theoretically effective, few data available
SVR 100% in 12/12 COMMAND 1 trial
Option 4IFN intolerant or ineligible
C2:R + SOF 24 wks „only preliminary data is available in
Egyptian pts“
TN 12 wks treatment: SVR 79% 11/14
TN 24 wks treatment: SVR 100% 14/14
TE 12 wks treatment: SVR 59% 10/17
TE 24 wks treatment: SVR 93% 14/15
Option 5 B2: SOF+SMV 12 wks Consider adding RBV in patients with predictors of poor response or
in pts with cirrhosis
„no data with this combination- it is likely that
data from Cosmos can be extrapolated“
Option 6 B2: SOF +DAC (60mg) 12 wks TN or 24wks TEConsider adding RBV in patients with predictors of poor
response or in pts with cirrhosis
„no data with this combination- it is likely that
data can be extrapolated“
![Page 13: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/13.jpg)
Introduction of HCV
Role of liver in glucose metabolism
link between HCV and DM.
Effect of control of DM on outcome of HCV
Effect of antiviral therapy on outcome of DM
Conclusion.
![Page 14: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/14.jpg)
The liver plays an important role in the regulation of glucose homeostasis. This helps explain why glucose intolerance is a feature or complication of chronic liver disease and cirrhosis
![Page 15: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/15.jpg)
Association between cirrhosis and impaired glucose metabolism
Up to 96% of patients with cirrhosis have diabetes or glucose intolerance (Hickman IJ, &
Macdonald GA, 2007).
It occurs in the absence of standard risk factors of type 2 diabetes such as age, body mass index and family history of diabetes (Holstein, etal 2002).
![Page 16: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/16.jpg)
The investigators noted that there is increasing evidence of a link between HCV and DM.
As the atherosclerosis risk in communities (ARIC) study reported that HCV infected individuals who were at risk for DM were 11 times more likely than those without HCV to develop overt DM
![Page 17: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/17.jpg)
Another study noted that the prevalence of HCV antibodies in diabetics were 4.39 folds higher than in nondiabetics .
More over , a study involved 1117 HCV and HBV patient , showed that the prevalence of DM was 21% in HCV patients and 12% in HBV patients
![Page 18: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/18.jpg)
Introduction of HCV
Role of liver in glucose metabolism
link between HCV and DM.
Effect of control of DM on outcome of HCV
Effect of antiviral therapy on outcome of DM
Conclusion.
![Page 19: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/19.jpg)
HCV infection has been suspected to affect glucose metabolism and predispose to insulin resistance ( IR ) and type 2 DM this may be due to
Direct pancreatic Beta cell destruction
Autoimmune Beta cell injury
Intracellular oxidative stress.
Dysregulation of cytokines
Inhibition of insulin downstream signaling.
Reduce expression of glucose transporters
![Page 20: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/20.jpg)
DM affects HCV patients by inducing Steatohepatitis which accelerate progression of liver diseases
IR with or without overt manifestations of DM adversely impact the clinical outcomes in HCV infected patients in terms of poor response to antiviral therapy , accelerated progression of liver fibrosis , and increased risk of HCC
![Page 21: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/21.jpg)
Introduction of HCV
Role of liver in glucose metabolism
link between HCV and DM.
Effect of control of DM on outcome of HCV
Effect of antiviral therapy on outcome of DM
Conclusion.
![Page 22: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/22.jpg)
Control of DM associated with good response
to traditional HCV treatment and reduce its
complications
![Page 23: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/23.jpg)
Introduction of HCV
Role of liver in glucose metabolism
link between HCV and DM.
Effect of control of DM on outcome of HCV
Effect of antiviral therapy on outcome of DM
Conclusion.
![Page 24: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/24.jpg)
Patients with HCV and DM had improved cardiovascular and renal outcomes when treated by antiviral therapy
Researchers analyised 1411 patients with both HCV and DM who received anti viral therapy (traditional therapy ) in comparison with the same number of patients who did not received antiviral therapy and 5644diabetics without HCV infections
![Page 25: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/25.jpg)
All patients were followed up for 8 years .
Results of the analysis revealed that, patients with both HCV and diabetes who received antiviral therapy, there was
1.1% incidence rate of end-stage kidney disease .
stroke incidence rate of 3.1% .
Heart attack incidence rate of 4.1%.
![Page 26: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/26.jpg)
Patients with both diabetes and HCV who were untreated had incidence rates for kidney disease, stroke and heart attack of 9.3%, 5.3% and 6.6% respectively,
while patients with diabetes who did not have HCV had a 3.3% incidence rate for kidney disease, 6.1% for stroke and 7.4% for heart attack.
![Page 27: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/27.jpg)
They concluded that :
HCV may cause clinical complications related to diabetes. But these issues are mitigated by HCV antiviral therapy, specifically pegylated interferon plus ribavirin, which was found to reduce risks of kidney disease, stroke and cardiovascular diseases in diabetic patients."
![Page 28: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/28.jpg)
Introduction of HCV
Role of liver in glucose metabolism
link between HCV and DM.
Effect of control of DM on outcome of HCV
Effect of antiviral therapy on outcome of DM
Conclusion.
![Page 29: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/29.jpg)
The liver plays an important role in glucose homeostasis
There is increasing evidence of a link between HCV and DM.
Traditional anti viral therapy improves DM outcomes , such as risk of Heart attack , stroke and renal diseases However DAAs needs more reaches to prove its efficacy .
Control of DM associated with good response to traditional HCV treatment and reduce its complications .
![Page 30: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/30.jpg)
New era of antiviral therapy (DAAs) showing excellent SVR in HCV eradication( SVR more than 90% ) However its role in reducing diabetic complications needs more and more studies to be proved .
![Page 31: Ueda2015 hcv dm dr.ahmed ali](https://reader034.fdocuments.in/reader034/viewer/2022042819/55cbba24bb61eb2d6d8b458c/html5/thumbnails/31.jpg)
Thank you